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Abstract In this study we have investigated hydroxyproline 
transport in rat heart mitochondria nd, in particular, in heart 
left ventricle mitochondria isolated from both spontaneously 
hypertensive and Wistar-Kyoto rats. Hydroxyproline uptake by 
mitochondria, where its catabolism takes place, occurs via a 
carrier-mediated process as demonstrated by the occurrence of 
both saturation kinetics and the inhibition shown by phenylsuc- 
cinate and the thiol reagent mersalyl. In any case, hydroxypro- 
line transport was found to limit the rate of mitochondrial 
hydroxyproline catabolism. A significant change in Vmax and Km 
values was found in mitochondria from hypertensive/hypertro- 
phied rats in which the Km value decreases and the Vma x value 
increases with respect to normotensive rats, thus accounting for 
the increase of hydroxyproline metabolism due to its increased 
concentration in a hypertrophic/hypertensive state. 
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major determinant of its architecture, structural integrity and 
mechanical properties [8]. 
In this paper, we first show HYP carrier-mediated uptake in 
rat heart mitochondria, after which investigation is made of 
HYP transport in left ventricle mitochondria in a study car- 
ried out with spontaneously hypertensive rats and normoten- 
sive Wistar-Kyoto rats, both at 5 and 24 weeks of age. This is 
worthy of special attention since both the collagen concentra- 
tion and the total amount of hydroxyproline content in the 
left ventricle were found to increase in spontaneously hyper- 
tensive rats as a result of increased fibroblastic activity in the 
pathogenesis of cardiac hypertrophy [8]. An increase in HYP 
translocator activity in hypertrophy/hypertension was shown. 
In all animals investigated, HYP transport across the mito- 
chondrial membrane was found to limit the HYP oxidation 
rate. 
2. Materials and methods 
1. Introduction 
Among the amino acids present in mammalian tissue pro- 
teins, 4-hydroxyproline (HYP) exhibits a special feature: it is 
limited essentially to collagen and its biosynthesis and catab- 
olism are therefore inseparably linked to these processes for 
collagen. In particular, HYP is released as a free compound 
from protease susceptible peptides and almost entirely catab- 
olized. The major pathway of HYP catabolism in rat tissue is 
defined principally by enzymatic studies [1,2]: the first oxi- 
dized product of HYP is 3-OH-P5C, whose formation is cat- 
alyzed by mitochondria [2]; subsequently 3-OH-P5C is oxi- 
dized further to 4-OH-GLU,  a substrate for a number of 
enzymes that act on glutamate, including transaminase [3], 
glutamine synthetase [4], glutaminase [5] and glutamate dehy- 
drogenase [6]. At present, in spite of the mitochondrial local- 
ization of HYP catabolism, its transport across the mitochon- 
drial matrix as well as the role of transport in HYP 
catabolism has not yet been exhaustively investigated. HYP 
transport has been studied in rat kidney mitochondria [7]; 
however, to date, no noteworthy information is available re- 
garding HYP transport in rat heart mitochondria, even 
though the myocardium contains a collagen matrix that is a 
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2.1. Chemicals 
All reagents were of finest available grade with all solutions being 
adjusted to pH 7.4 by the addition of either Tris or HCI. 
2.2. Animals 
Two groups of male animals (Charles River) were used: sponta- 
neously hypertensive rat and Wistar-Kyoto rats, with the latter used 
as a control. 5- and 24-week-old animals were considered for each 
group. 
2.3. Arterial blood pressure and left ventricular mass index 
Arterial blood pressure was measured by using the tail-cuff plethys- 
mographic method (LE 5000 digital pressure meter, LETICA). The 
instrument functions by causing artery collapse (sphygmomanometer), 
utilizing pressure produced by a cuff; blood pulses are picked up by 
an appropriate transducer unit. 
The values were taken at least three times with the mean value 
being reported. 
2.4. Left ventricular hypertrophy 
Left ventricular hypertrophy, determined by using the left ventricu- 
lar mass index, was calculated based on the following formula: ven- 
tricle weight/body weightx 103 [9 11]. 
2.5. Isolation of mitochondria 
Spontaneously hypertensive and Wistar-Kyoto male rats weighing 
150 350 g (5 and 24 weeks old, respectively) were anesthetized with 
ether, killed, and their hearts rapidly removed. 10 and 4 rats were used 
in a single preparation with 5- and 24-week-old rats, respectively. The 
left ventricle was isolated after trimming both atria, right ventricle and 
connective tissue. 
Mitochondria from either at whole heart or rat heart left ventricle 
were isolated essentially according to [12], using a medium consisting 
of 0.25 M sucrose, 20 mM Tris-HC1 pH 7.25, 1 mM EGTA. The final 
mitochondrial pellet was suspended in the isolation medium to obtain 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
PHS0014-5793(96)01  I 14-3 
280 
30~40 mg protein/ml with mitochondrial protein measured according 
to [13]. 
Since coupled mitochondria re strictly required to investigate 
properly oxidative phosphorylation, control was performed, via the 
respiratory chain, in each experiment of the mitochondrial integrity 
and effectiveness in electron flow. In order to do so, oxygen uptake 
measurements were carried out at 25°C in 2 ml of a medium consist- 
ing of 100 mM NaCI, 10 mM MgC12, 10 mM sodium phosphate 
buffer, l0 mM Tris-HC1 pH 7.4, by means of a Gilson 5\6 oxygraph 
using a Clark electrode. Our mitochondrial preparations showed a 
respiratory control ratio, i.e. the ratio between the rate of 02 con- 
sumption in state 3 (in the presence of ADP) and the rate in state 4 (in 
the absence of ADP), in the range 3-5. Moreover P/O ratios, i.e. the 
mole equivalents of phosphate sterified per mole oxygen consumed, 
were 3.0 _+ 0.3, 2.3 _+ 0.8 and 1.2 + 0.2 as obtained by using glutamate 
plus malate, succinate and ascorbate plus TMPD as respiratory sub- 
strates, respectively. 
2.6. Fluorimetric assay 
Changes in the redox state of the pyridine nucleotide were followed 
fluorimetrically using a Perkin-Elmer luminometer LS-5 with excita- 
tion and emission wavelengths set at 334 and 456 nm, respectively. 
HYP uptake was monitored, according to [7], following intramito- 
chondrial NAD(P) + reduction caused by externally adding the sub- 
strate to mitochondria previously incubated with 1.25 p.M FCCP, to 
increase the intramitochondrial NAD(P) + concentration, and supple- 
mented, 2 min later, with 2 gg rotenone, to prevent oxidation of the 
newly synthesized NAD(P)H via the respiratory chain. The rate of 
fluorescence hange was measured as the tangent to the initial part of 
the experimental curve and expressed as nmol intramitochondrial 
NAD(P) + reduced/min per mg mitochondrial protein. In order to 
obtain a quantitative measurement of the rate of intramitochondrial 
NAD(P) + reduction, the fluorimetric response was calibrated as in 
[14]. 
2.7. Statistical analysis' and computing 
Results are expressed as mean values+S.E.M. Statistical signifi- 
cance was determined by Student's t-test. Where necessary, experi- 
mental plots were obtained by means of Grafit software (Erithacus). 
3. Results 
3.1. Spectroscopic study o f  hydroxyproline transport in rat 
whole heart mitochondria 
As expected in the light of mitochondrial localization of 
HYP-catabolizing enzymes ([2,7]; Fig. 1), the addition of 
HYP to rat heart mitochondria, preincubated with the uncou- 
pler FCCP and then supplemented with rotenone, causes a 
rapid increase in fluorescence of the intramitochondrial pyr- 
idine nucleotides (not shown). In fact, HYP in the mitochon- 
drial matrix is oxidized to 4 -OH-GLU via HYP oxidase and 
3-OH-P5C dehydrogenase with simultaneous reduction of the 
intramitochondrial NAD(P) + (Fig. 1). In order to gain an 
initial insight into the occurrence of carrier-mediated HYP 
transport, in the same experiment we also examined the ability 
of mersalyl and phenylsuccinate, used as impermeable inhibi- 
tors of certain mitochondrial carriers [15-18], to affect the rate 
of fluorescence increase. Both mersalyl (250 laM) and phenyl- 
succinate (5 mM) significantly decreased (about 55 and 40%, 
respectively) the rate of intramitochondrial NAD(P)H forma- 
tion (not shown), thus suggesting that HYP transport is a 
carrier-mediated process. 
On the basis of these findings, the question arises as to 
which step in HYP metabolism can limit the rate of 
NAD(P)H formation in vitro and likely in vivo. Indeed, since 
this could reflect either the rate of HYP uptake or the rate of 
one of the intramitochondrial reactions, investigation was 
made to determine the rate-limiting step in mitochondrial 
HYP catabolism. We found that Triton experiments failed 
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Fig. 1. Mechanism of mitochondrial HYP transport. 
to elucidate this point: in fact, as in [7,17,18], externally added 
Triton completely prevents any change of fluorescence (not 
shown). Accordingly, as advised (see [7,17-20]), control 
strength criteria were applied by using the inhibitor phenyl- 
succinate, which can inhibit HYP transport but not catabo- 
lism, since it is a non-penetrant compound [15]. Thus, the 
dependence of the rate of fluorescence increase due to exter- 
nally added HYP in either the absence or presence of increas- 
ing phenylsuccinate concentrations was studied as a Dixon 
plot (Fig. 2A). Phenylsuccinate inhibits the rate of fluores- 
cence increase caused by externally HYP in a competitive 
manner (Ki = 2.5 mM). It should be noted that if the recipro- 
cal of the rate of investigated reactions is plotted against in- 
hibitor concentrations, the resulting Dixon plot extrapolated 
to zero inhibition provides a measure of the inhibited process, 
i.e. the transport (see [7,17-20]). In Fig. 2A, the intercept o 
the ordinate axis of the line given by linear regression analysis 
of the experimental points obtained in the presence of the 
inhibitor coincides with the experimental point obtained in 
the absence of phenylsuccinate; this shows that the measured 
rate of NAD(P) reduction reflects the rate of HYP transport 
across the mitochondrial membrane, i.e. the rate of HYP cat- 
abolism depends on HYP transport across the mitochondrial 
membrane, under these experimental conditions. 
In another set of experiments, the dependence of the HYP 
uptake rate versus HYP concentration was investigated by 
means of a double-reciprocal p ot (by using Grafit Software) 
(Fig. 2B). HYP uptake reveals hyperbolic saturation charac- 
teristics: the Kin, i.e. the HYP concentration which gives half- 
maximum rate of NAD(P)H formation, and Vmax values were 
1.3 mM and 6 nmol/min per mg protein. 
3.2. Arterial blood pressure and left ventricular mass index 
In order to check metabolic alterations in both the initial 
and mature hypertension states, 5- and 24-week-old rats were 
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Fig. 2. Fluorimetric investigation of HYP uptake by rat heart mitochondria. Mitochondria (0.8 mg protein) from rat whole heart were preincu- 
bated at 20°C for 1 min in 2.0 ml of incubation medium consisting of 0.2 M sucrose, 10 mM KC1, 20 mM HEPES-Tris pH 7.2, 1 mM MgCl2 
in the presence of 1.25 I.tM FCCP and 2 btg rotenone (for details see Section 2). The HYP uptake reaction was started with hydroxyproline ad- 
dition. (A) Dixon plot of the inhibition by phenylsuccinate. Phenylsuccinate (5 mM) was added 1 rain before the addition of substrate. The re- 
duction rate of intramitochondrial NAD(P) + was measured by using 0.7 mM (closed symbols) and 2 mM (open symbols) HYP in the absence 
or presence of phenylsuccinate at the indicated concentrations. (B) Kinetic analysis of HYP uptake. HYP was added at the indicated concentra- 
tions. The rate measured as the tangent o the initial part of the progress curve is expressed as nmol NAD(P) + reduced/min per mg mitochon- 
drial protein. 
used, with their arterial blood pressure and left ventricular 
mass index tested first. No significant difference in arterial 
blood pressure was found when comparing 5-week-old spon- 
taneously hypertensive and Wistar-Kyoto rats (123 + 10 and 
115+9 mmHg,  respectively) whereas, in agreement with 
[11,21-23], the systolic blood pressure values were significantly 
different in spontaneously hypertensive and Wistar-Kyoto rats 
at the 24th week of life (spontaneously hypertensive rats, 
214+ 14 mmHg;  Wistar-Kyoto rats, 139+ 12 mmHg;  
p < 0.001). 
A progressive increase in left ventricular mass index was 
measured with age in spontaneously hypertensive rats when 
compared to Wistar-Kyoto rats: the significant difference re- 
ported at the 5th week of age (spontaneously hypertensive 
rats, 3 .1+0.3;  Wistar-Kyoto rats, 2 .5+0.3;  p<0.05) ,  in 
agreement with [9,23,11], became consistent and more signifi- 
cant at the 24th week (spontaneously hypertensive rats, 
3.4 + 0.3 ; Wistar-Kyoto rats, 2.2 + 0.3; p < 0.001). Interest- 
ingly, left ventricular mass indexes were found to be statisti- 
cally different in 5- and 24-week-old spontaneously hyperten- 
sive rats (p < 0.03). 
Thus, as no significant change in blood pressure was found 
in 5-week-old spontaneously hypertensive rats, this study as- 
sumes that they represent a model in which any biochemical 
change might be related to ventricle hypertrophy (hyper- 
trophic state). In contrast, since in 24-week-old spontaneously 
hypertensive rats biochemical alterations hould be considered 
in the light of the increase of both blood pressure and ven- 
tricular mass, they are assumed to be the result of a hyper- 
trophic/hypertensive state. 
3.3. Spectroscopic study of HYP uptake into spontaneously 
hypertensive rat heart left ventricle mitochondria 
As HYP  concentrat ion and metabol ism increase strongly in 
the hypertensive/hypertrophic states, comparison was made of 
heart left ventricle mitochondr ia from spontaneously hyper- 
tensive rats and normotensive strain 'control' ,  in terms of 
their ability to internalize HYP. In this case, rat heart left 
ventricle mitochondr ia were used from both 5- (hypertrophic 
state) and 24-week-old (hypertrophic/hypertensive tate) ani- 
mals. As shown in Fig. 3, when using 24-week-old rats (C,D) 
the rate of fluorescence increase caused by externally added 
HYP (1 mM) was found to increase in spontaneously hyper- 
tensive rats (350%) compared to that found when using age- 
matched Wistar-Kyoto rats, whereas an approximately equal 
rate value was found when animals at the fifth week of age 
were used (A,B). 
The HYP  uptake induced fluorescence change appears to 
follow a first-order type reaction as calculated by plotting 
2.3"Iog(FHyp)MAX/([FHyp]MAx--[FHyP]), where (FHyp)MAX = 
maximum fluorescence change, i.e. HYP accumulated, meas- 
ured after equil ibrium is reached, versus the indicated times t: 
the value of the first-order constant is about 0.6 min -1 for 
both normotensive rats at 5 and 24 weeks and spontaneously 
Table 1 
Kinetic parameters of HYP transport in both 5- and 24-week-old spontaneously h pertensive or Wistar-Kyoto rat heart left ventricle mitochon- 
dria 
HYP translocator SH5 WKY5 SH24 WKY24 
Km (mM) 1.3+0.15 1.2-+0.09 0.4-+0.06 1.1 +0.12 
Vmax (nmol/min per mg) 6.3 + 0.20 5.2 + 0.12 12.7 + 0.27 5.5 + 0.16 
Experimental conditions for the measurement of activity of HYP carrier in mitochondria from either 5- and 24-week old spontaneously h perten- 
sive (SH) and Wistar-Kyoto (WKY) rats were as described in Section 2 and Fig. 2. 
Km and Vm~ values were calculated from a double-reciprocal plot obtained with three independent determinations of the rate of transport. 
Values are reported as means + standard error as calculated by Grafit software. 
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Fig. 3. Hydroxyproline uptake by rat heart left ventricle mitochondria from either 5- and 24-week-old spontaneously hypertensive or Wistar- 
Kyoto rats. Either 5- and 24-week-old spontaneously hypertensive rat heart left ventricle mitochondria (A,C) or 5- and 24-week-old Wistar- 
Kyoto rat heart left ventricle mitochondria (B,D) (each 0.6 mg protein) were suspended at 20°C for 1 min in 2.0 m] of incubation medium in 
the presence of 1.25 pM FCCP and 2 pg rotenone (experimental conditions as in Fig. 2). Where indicated, 1 mM hydroxyproline (1 mM, 
HYP) was added. Mersalyl (250 pM, MERS) was added 1 min before substrate addition. The numbers along the curves represent the rate 
measured as the tangent o the initial part of the progress curve, expressed as nmol NAD(P) + reduced/min per mg mitochondrial protein. In- 
set: logarithmic plot of HYP uptake induced fluorescence change value (FHyp), demonstrating first-order kinetics: 2.3"Iog(FHyp)MAX/ 
[(Ftyp)MAx--(FHyp)] =kt, where (FHyp).XlAX = maximum fluorescence change measured, i.e. HYP accumulated, after equilibrium is reached. 
hypertensive mitochondria from 5-week-old animals, i.e. in 
the hypertrophic state (see insets a,b,d of Fig. 3), and 2.4 
min -1 for spontaneously hypertensive rats at 24 weeks of 
age, i.e. in a hypertrophic/hypertensive state (see inset c of 
Fig. 3). In any case, mersalyl inhibits the process (Fig. 3); 
the nature of inhibition is non-competitive as determined 
from Dixon plots (Fig. 4). The Ki values for mersalyl were 
500 and 280 pM for spontaneously hypertensive and 500 and 
450 I.tM for Wistar-Kyoto mitochondria from 5- and 24-week- 
old rats, respectively. This shows that HYP carrier contains -
SH group(s) located far from the substrate binding site. It 
should be noted that the mersalyl experiment provides evi- 
dence that HYP oxidation reflects the rate of the transport 
(see above) in both spontaneously hypertensive and Wistar- 
Kyoto rats at 5 and 24 weeks of age. The differences in Ki 
values, which reflect inhibitor affinity for the carrier, initially 
suggest that the carrier molecule is significantly modified in 
the hypertrophic/hypertensive tate. When investigation of the 
dependence of the HYP transport rate on externally added 
HYP was carried out, saturation kinetics were found in all 
cases. In Table 1 comparison is made of mitochondria from 
spontaneously hypertensive and Wistar-Kyoto rats, both at 5 
and 24 weeks of age, with respect to the kinetic parameters. 
The p values obtained by statistically evaluating the measure- 
ments of 3 experiments confirm that significant differences in 
both Km and Vm~ values are found between the 24-week-old 
spontaneously hypertensive and the other mitochondria, as 
described in Table 1 (p < 0.05). By assuming the HYP cyto- 
solic concentration to be about 1 mM (see [24-26]), actual 
rates of 2.8 and 9.3 nmol taken up HYP/min per mg mito- 
chondrial protein for spontaneously hypertensive rats can be 
calculated in the hypertrophic and hypertrophic/hypertensive 
state, respectively (in age-matched Wistar-Kyoto rat heart left 
ventricle mitochondria the rates are 2 and 2.7 nmol/min per 
mg protein, respectively). 
4. Discussion 
The results reported in this paper lead to the conclusions 
that both HYP uptake into rat whole heart mitochondria 
occurs via a carrier-mediated process and that the rat heart 
left ventricle mitochondria tested differ from each other (spon- 
taneously hypertensive with respect o Wistar-Kyoto rats) as 
far as hypertrophy/hypertension is concerned. In particular, 
we observed an increase in HYP catabolism due to the in- 
crease in HYP carrier activity which allows for HYP uptake 
by mitochondria where its catabolism takes place. At present, 
the reason for the increased Vm~× and decreased Km values 
still needs to be established. The carrier activity increase ob- 
served at the 24th week of life in spontaneously hypertensive 
rats is consistent with increased collagen concentration which 
requires an increase in catabolism [27,28]; thus, the increase in 
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Fig. 4. Dixon plot of the inhibition by mersalyl of the rate of fluorescence increase due to externally added HYP to either 5- and 24-week-old 
spontaneously hypertensive or Wistar-Kyoto rat heart left ventricle mitochondria. Rat heart left ventricle mitochondria (0.6 mg protein) from 
either 5- and 24-week-old spontaneously hypertensive (A,C) or age-matched Wistar-Kyoto rats (B,D) were suspended at 20°C for 1 min in 2 
ml of incubation medium in the presence of 1.25 gM FCCP and 2 gg ROT (experimental conditions as in Fig. 2). The rate of reduction of in- 
tramitochondrial NAD(P) + was measured by using 1 mM (open symbols) and 10 mM (closed symbols) HYP in the absence or presence of 
mersalyl at the indicated concentration. The rate is expressed as nmol NAD(P) + reduced/min per mg mitochondrial protein. 
HYP transport rate may be assumed to be an adaptative 
response of the heart to an imposed work overload [29]. On 
the other hand, given that the sustained pressure load in spon- 
taneously hypertensive rats is responsible for changes in car- 
diac function and energy metabolism and, ultimately, in the 
development of cardiac hypertrophy, adaptation of the heart 
to a high cardiac work load could lead both to changes in the 
activity of enzyme systems of myocardial energy production 
and to new synthesis of structural proteins [30-34], including 
the mitochondrial carriers. Thus, a change in Vm~, could be 
due to an increase in the number of carrier proteins (due to 
genetic alterations), however, a change in the membrane car- 
rier environment, which might increase the specific carrier 
activity cannot be ruled out. On the other hand, a change 
in Km suggests a modification in the substrate binding site, 
assumed to be consistent with a change in the carrier molecule 
structure (see mersalyl experiment). Nevertheless, given that 
non-hemodynamic factors, such as circulating hormones, also 
represent growth stimuli to cardiac fibroblasts and contribute 
to structural remodeling of the cardiac interstitium during 
hypertension, it may be reasonable to suggest a role for these 
factors in the catabolic pathway of collagen [35]; indeed, col- 
lagenase activity was found to be affected by angiotensin II 
[36,371. 
A better understanding of the pathophysiological basis for 
fibrosis and the mechanisms responsible for fibroblast col- 
lagen turnover is of particular importance in hypertension 
because of the varied alterations in cardiac performance at 
different stages [38,39], and the possibility of reversing abnor- 
mal accumulation of fibrillar collagen with antihypertensive 
therapy [4043]. 
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